<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3332426</article-id><article-id pub-id-type="publisher-id">ar3664</article-id><article-id pub-id-type="doi">10.1186/ar3664</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Cryer</surname><given-names>Byron</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Li</surname><given-names>Chunming</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Simon</surname><given-names>Lee S</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Singh</surname><given-names>Gurkirpal</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Stillman</surname><given-names>Martin J</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Berger</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Texas Southwestern Medical Center, Dallas, TX, USA</aff><aff id="I2"><label>2</label>Pfizer Inc. New York, NY, USA</aff><aff id="I3"><label>3</label>SDG, LLC, Cambridge, MA, USA</aff><aff id="I4"><label>4</label>Stanford University, Palo Alto, CA, USA</aff><aff id="I5"><label>5</label>Hennepin County Medical Center, Minneapolis, MN, USA</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>9</day><month>2</month><year>2012</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)</named-content><ext-link ext-link-type="uri" xlink:href="1478-6354-14-S1.pdf">1478-6354-14-S1.pdf</ext-link></supplement><fpage>P63</fpage><lpage>P63</lpage><permissions><copyright-statement>Copyright &#x000a9;2012 Cryer et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cryer et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://arthritis-research.com/content/14/S1/P63"/><conference><conf-date>14-16 November 2011</conf-date><conf-name>8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)</conf-name><conf-loc>Tokyo, Japan</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>The GI Randomized Event and Safety Open-Label NSAID Study (GI-REASONS) was a novel prospective, randomized, open-label, blinded end point (PROBE) study that measured adjudicated clinical outcomes throughout the GI tract. It was designed to assess if celecoxib use in patients with osteoarthritis (OA) at moderate GI risk (&#x02265;55 y) is associated with a lower incidence of clinically significant upper and lower GI events compared to nsNSAIDs, with/without proton-pump inhibitors (PPIs), in standard US clinical practice.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>8067 OA patients were randomized 1:1 for 6-mos with celecoxib or a nonselective (ns)NSAID, stratified by <italic>H pylori </italic>status. The primary end point was a composite of adjudicated clinically significant upper and lower GI events. Aspirin use was not permitted. Treatment doses could be adjusted per US prescribing information. Patients randomized to the nsNSAID arm could switch between nsNSAIDs; however, crossover between treatment arms was not allowed. PPIs and histamine-2 receptor antagonists (H<sub>2</sub>RAs) were prescribed at the providers' discretion.</p></sec><sec><title>Results</title><p>4035 celecoxib and 4032 nsNSAID patients were randomized and included in the ITT analyses. Baseline demographics were similar. Overall, significantly more nsNSAID users met the primary end point at 6 mos (OR, 1.82; 95% CI 1.31-2.55; <italic>p </italic>= 0.0003; Table <xref ref-type="table" rid="T1">1</xref>). The most commonly used nsNSAIDs were meloxicam (42%), naproxen (21%), diclofenac (20%) and nabumetone (14%). 2596 celecoxib (64.3%) and 2611 (64.8%) nsNSAID users completed the study. 189 patients were lost to follow-up (LTFU; 2.1% celecoxib and 2.6% nsNSAID). Attributing the primary end point to all LTFU patients (worst-case sensitivity analysis), celecoxib remained superior (OR 1.46; 95% CI 1.18-1.82; <italic>p </italic>= 0.0006). AEs, SAEs and discontinuations were similar in both treatment groups. 23% of celecoxib and 24% of nsNSAID patients used a PPI (<italic>p </italic>= NS). Moderate to severe abdominal symptoms were experienced by 94 (2.3%) celecoxib and 138 (3.4%) nsNSAID patients (<italic>P</italic>&#x0003c;.01).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Clinically significant upper and lower GI events: primary analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="left" colspan="2">Celecoxib</th><th align="left" colspan="2">nsNSAID</th></tr><tr><th/><th colspan="5"><hr/></th></tr><tr><th/><th/><th align="left">N</th><th align="left">Patients With Event n (%)</th><th align="left">N</th><th align="left">Patients With Event n (%)</th></tr></thead><tbody><tr><td align="left" colspan="2"><bold>All patients</bold></td><td align="left">4035</td><td align="left">54 (1.3)</td><td align="left">4032</td><td align="left">98 (2.4)</td></tr><tr><td colspan="6"><hr/></td></tr><tr><td align="left"><bold><italic>H pylori </italic>status</bold></td><td align="left"><bold>Positive</bold></td><td align="left">1401</td><td align="left">25 (1.8)</td><td align="left">1386</td><td align="left">34 (2.5)</td></tr><tr><td/><td colspan="5"><hr/></td></tr><tr><td/><td align="left"><bold>Negative</bold></td><td align="left">2634</td><td align="left">29 (1.1)</td><td align="left">2646</td><td align="left">64 (2.4)</td></tr><tr><td colspan="6"><hr/></td></tr><tr><td align="left" colspan="2"><bold>OR (95% CI); P value</bold></td><td align="left" colspan="4">1.82 (1.31-2.55); <italic>p </italic>= 0.0003</td></tr></tbody></table></table-wrap></sec><sec><title>Conclusion</title><p>Celecoxib use had a lower risk of clinically significant upper and lower GI events than nsNSAIDs. A major strength of this study is its PROBE design. Simple inclusion and exclusion criteria allowed for a broad patient population of moderate GI risk. Switching among nsNSAIDs and allowing for dose adjustments, along with use of PPIs and H<sub>2</sub>RAs as needed, more closely reflects daily clinical practice. GI-REASONS demonstrates the improved GI safety profile of celecoxib throughout the GI tract in patients treated in a "real-world" setting.</p></sec></body></article>